Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRK Merck & Co., Inc.	$123.93 +0.3%	$119.12	$76.66 ▼ $130.29	$305.12B	0.19	10.67 million shs	5.19 million shs
PCVX Vaxcyte	$57.03 -2.0%	$52.18	$29.08 ▼ $65.00	$8.41B	1.22	1.82 million shs	831,066 shs
PFE Pfizer	$24.46 +1.2%	$25.32	$23.11 ▼ $28.75	$137.76B	0.35	47.17 million shs	42.73 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRK Merck & Co., Inc.	+0.17%	-2.25%	+4.10%	+3.33%	+48.69%
PCVX Vaxcyte	-2.03%	+0.12%	+20.16%	-9.13%	+58.73%
PFE Pfizer	+1.02%	+3.04%	-6.60%	-9.84%	-4.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRK Merck & Co., Inc.	$123.93 +0.3%	$119.12	$76.66 ▼ $130.29	$305.12B	0.19	10.67 million shs	5.19 million shs
PCVX Vaxcyte	$57.03 -2.0%	$52.18	$29.08 ▼ $65.00	$8.41B	1.22	1.82 million shs	831,066 shs
PFE Pfizer	$24.46 +1.2%	$25.32	$23.11 ▼ $28.75	$137.76B	0.35	47.17 million shs	42.73 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRK Merck & Co., Inc.	+0.17%	-2.25%	+4.10%	+3.33%	+48.69%
PCVX Vaxcyte	-2.03%	+0.12%	+20.16%	-9.13%	+58.73%
PFE Pfizer	+1.02%	+3.04%	-6.60%	-9.84%	-4.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MRK Merck & Co., Inc.	2.70	Moderate Buy	$133.94	8.08% Upside
PCVX Vaxcyte	2.63	Moderate Buy	$86.00	50.80% Upside
PFE Pfizer	2.19	Hold	$28.50	16.51% Upside

Current Analyst Ratings Breakdown

Latest PCVX, PFE, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/13/2026	MRK Merck & Co., Inc.	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$135.00 ➝ $140.00
7/13/2026	MRK Merck & Co., Inc.	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$135.00 ➝ $142.00
7/13/2026	MRK Merck & Co., Inc.	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$140.00 ➝ $145.00
7/13/2026	PFE Pfizer	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$34.00 ➝ $30.00
7/13/2026	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$36.00 ➝ $35.00
7/10/2026	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$27.00 ➝ $26.00
7/9/2026	MRK Merck & Co., Inc.	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$112.00 ➝ $113.00
7/8/2026	MRK Merck & Co., Inc.	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$142.00
7/8/2026	MRK Merck & Co., Inc.	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$145.00 ➝ $150.00
7/8/2026	PFE Pfizer	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$30.00 ➝ $28.00
7/6/2026	PCVX Vaxcyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MRK Merck & Co., Inc.	$65.01B	4.71	$11.46 per share	10.81	$21.22 per share	5.84
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A
PFE Pfizer	$62.58B	2.23	$4.45 per share	5.50	$15.26 per share	1.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MRK Merck & Co., Inc.	$18.25B	$3.55	34.91	12.52	2.65	13.59%	27.55%	10.73%	8/4/2026 (Estimated)
PCVX Vaxcyte	-$766.63M	-$6.88	N/A	N/A	N/A	N/A	-32.51%	-29.51%	8/5/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	18.67	8.55	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)

Latest PCVX, PFE, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.0556	N/A	N/A	N/A	$12.50 million	N/A
8/4/2026	Q2 2026	MRK Merck & Co., Inc.	$2.15	N/A	N/A	N/A	$16.40 billion	N/A
8/4/2026	Q2 2026	PFE Pfizer	$0.68	N/A	N/A	N/A	$14.41 billion	N/A
5/6/2026	Q1 2026	PCVX Vaxcyte	-$1.7411	-$2.30	-$0.5589	-$2.30	$12.50 million	N/A
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
4/30/2026	Q1 2026	MRK Merck & Co., Inc.	-$1.47	-$1.28	+$0.19	-$1.72	$15.85 billion	$16.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MRK Merck & Co., Inc.	$3.40	2.74%	+5.75%	95.77%	14 Years
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.03%	-13.20%	131.30%	16 Years

Latest PCVX, PFE, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/24/2026	PFE Pfizer	quarterly	$0.43	7.15%	7/24/2026	7/24/2026	9/1/2026
5/26/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.96%	6/15/2026	6/15/2026	7/8/2026
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MRK Merck & Co., Inc.	1.02	1.30	1.06
PCVX Vaxcyte	N/A	7.49	7.49
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MRK Merck & Co., Inc.	76.07%
PCVX Vaxcyte	96.78%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
MRK Merck & Co., Inc.	0.17%
PCVX Vaxcyte	3.30%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.47 billion	Optionable
PCVX Vaxcyte	160	144.40 million	139.63 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

PCVX, PFE, and MRK Headlines

Recent News About These Companies

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

49 minutes ago | fool.com

Pfizer Inc. $PFE Shares Sold by Calamos Advisors LLC

2 hours ago | marketbeat.com

Can Pfizer (NYSE:PFE) Reinforce Its Value Stock Appeal?

July 13 at 8:32 PM | kalkinemedia.comK

Pfizer (PFE) Advances While Market Declines: Some Information for Investors

July 13 at 8:32 PM | finance.yahoo.com

Pfizer (PFE) Advances While Market Declines: Some Information for Investors

July 13 at 6:45 PM | zacks.com

Pfizer (NYSE:PFE) Stock Price Up 1.2% - What's Next?

July 13 at 5:20 PM | marketbeat.com

Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?

July 13 at 4:50 PM | 247wallst.com

Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?

July 13 at 4:47 PM | 247wallst.com

2 Value Stocks Worth Your Attention and 1 Facing Headwinds

July 13 at 3:31 PM | finance.yahoo.com

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions (PFE)

...

July 13 at 12:25 PM | marketbeat.com

How Does LLY Stock Reach $2,100?

July 13 at 10:30 AM | trefis.comT

What It Means To Hold Moderna Stock In A Crash

July 13 at 10:30 AM | trefis.comT

Pfizer (NYSE:PFE) Given New $30.00 Price Target at BMO Capital Markets

July 13 at 9:11 AM | marketbeat.com

Pfizer (NYSE:PFE) Price Target Cut to $35.00 by Analysts at Guggenheim

July 13 at 8:59 AM | marketbeat.com

Triglav Investments D.O.O. Has $8.89 Million Position in Pfizer Inc. $PFE

July 13 at 6:00 AM | marketbeat.com

Pfizer Inc. $PFE Shares Purchased by CORDA Investment Management LLC.

July 13 at 4:07 AM | marketbeat.com

Diversify Wealth Management LLC Has $3.35 Million Position in Pfizer Inc. $PFE

July 13 at 3:59 AM | marketbeat.com

Citizens Financial Group Inc. RI Trims Stock Holdings in Pfizer Inc. $PFE

July 13 at 3:44 AM | marketbeat.com

LGT Fund Management Co Ltd. Buys 765,044 Shares of Pfizer Inc. $PFE

July 12 at 1:44 PM | marketbeat.com

Pfizer Inc. $PFE Shares Sold by International Assets Investment Management LLC

July 12 at 1:44 PM | marketbeat.com

Pfizer Inc. $PFE Position Lifted by Fifth Third Bancorp

July 12 at 11:19 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCVX, PFE, and MRK Company Descriptions

Merck & Co., Inc. NYSE:MRK

$123.93 +0.39 (+0.32%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$124.19 +0.26 (+0.21%)

As of 06:12 AM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Vaxcyte NASDAQ:PCVX

$57.03 -1.18 (-2.03%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$57.04 +0.00 (+0.01%)

As of 04:28 AM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Pfizer NYSE:PFE

$24.46 +0.29 (+1.20%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$24.48 +0.02 (+0.08%)

As of 06:19 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PCVX, PFE, and MRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PCVX, PFE, and MRK Earnings

Compare Dividends

Latest PCVX, PFE, and MRK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PCVX, PFE, and MRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCVX, PFE, and MRK Company Descriptions

Merck & Co., Inc. NYSE:MRK

Vaxcyte NASDAQ:PCVX

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PCVX, PFE, and MRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PCVX, PFE, and MRK Earnings

Compare Dividends

Latest PCVX, PFE, and MRK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PCVX, PFE, and MRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCVX, PFE, and MRK Company Descriptions

Merck & Co., Inc. NYSE:MRK

Vaxcyte NASDAQ:PCVX

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools